Visiongain says ‘ Global Precision Medicine Market Set To Grow To $83bn By 2022’

01 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Precision Medicine Market Forecast 2018-2028: Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases

Precision medicine is one of the trends in the healthcare industry which has shown tremendous level of progress in the last few years. The focus of healthcare industry has shifted towards personalized medicine, also known as precision medicine or individualized medicine since 2003 with the complete sequencing of human genome. This industry is gaining attention due to the flourishing growth of personal healthcare devices, integration of smart technologies into healthcare, and collaborations of healthcare and IT firms with pharmaceutical and biotechnology companies. The precision medicine data contents and services are accessed by health providers, consumers (patients), and other related users for the improvement of healthcare system and more accurate treatments.

The lead analyst of the report commented “One of the emerging opportunities for the global precision medicine market is the increasing number of patients suffering from genetic diseases in developing countries that include Asia-Pacific countries and many Middle-East and African countries. The growth of the global precision medicine market is dependent on widespread network coverage and access to mobile devices. As the network coverage is expanding at a high rate across the globe, the demand for consumer usage as well as policies to stimulate growth in telecommunications infrastructure is rising.”

Leading companies featured in the report include Abbott Laboratories, GE Healthcare, GlaxoSmithKline (GSK), Johnson & Johnson, Pfizer, Laboratories Corporation of America Holdings, Danaher Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever